Fig. 4 | Scientific Reports

Fig. 4

From: Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases

Fig. 4The alternative text for this image may have been generated using AI.

Overview of Circulating Tumor DNA Process. Exceptional responders were identified from consecutive oligometastatic patients treated between 2014 and 2021. A clinically validated, personalized, tumor-informed 16-plex mPCR-NGS assay (SignateraTM, Natera Inc), was used to detect molecular residual disease (MRD). The Signatera assay is based on whole-exome sequencing of the tumor and a matched normal blood sample to detect and quantify ctDNA. Created with BioRender.com.

Back to article page